The SMA gene therapy candidate OAV101 IT, a version of Zolgensma, can be safely given to previously treated patients, per new ...

Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with sales now heading into reverse, the company is looking to extend its franchise.

Shane here! I just wanted to quick put up some reflections on my day today. I got my 7th Spinraza injection and it was quite a long day! Manfred considering petition to have Rose posthumously ...

Spinraza (nusinersen), by Biogen ... Administered intravenously (into the vein) through a single infusion, Zolgensma uses a modified and harmless viral shell to deliver a healthy copy of the SMN1 gene ...

There was no treatment until Doctor Adrian Krainer with Cold Spring Harbor lab on Long Island led the way to creation of Spinraza, a first FDA-approved treatment for Spinal Muscular Atrophy.

The approval of this new tablet builds on previous successes in SMA treatment, joining the existing oral liquid version of risdiplam (Evrysdi), as well as Biogen’s nusinersen (Spinraza) and Novartis ...

However while Spinraza had a very strong launch in the first half of 2017, its US sales faltered in Q3 to $197.6 million, barely above the $194.8 million achieve in the previous quarter.